Background {#Sec1}
==========

Heart failure (HF) has significant morbidity and is often a result of impaired left ventricular myocardial function \[[@CR1]\]. HF with preserved ejection fraction (HFpEF) involves impaired myocardial function with normal left ventricle size and ejection fraction; in contrast, HF with reduced ejection fraction (HFrEF) involves an enlarged left ventricle size and reduced ejection fraction. Evidence-based HF treatment reduces morbidity and mortality in HFrEF \[[@CR2]\]. HFpEF prevalence is rising due to an ageing population, however, there are no treatments which reduce morbidity and mortality \[[@CR3]\]. Diagnosing HFpEF is often confounded by the occurrence of similar symptoms in patients with multiple medical comorbidities \[[@CR3]\]. The most prevalent risk factor for HFpEF is hypertension \[[@CR3]\]. Several RCTs have explored the benefits of β-blockers \[[@CR4]\], ARBs \[[@CR5]\], ACEi \[[@CR6]\], and mineralocorticoid receptor antagonists (MRAs) \[[@CR7]\] in HFpEF and identified trends towards reduced cardiovascular morbidity and mortality \[[@CR8]\]. The lack of strong evidence in HFpEF treatment has led to considerable treatment variation \[[@CR9]\].

MRAs can be selective (e.g., eplerenone) or nonselective (e.g., spironolactone). Eplerenone was synthesized through chemical modification of spironolactone in order to enhance binding of mineralocorticoid receptors while reducing off-target binding to progesterone or androgen receptors \[[@CR10]\]. Eplerenone is associated with lower rates of impotence, gynecomastia or breast pain in comparison to spironolactone \[[@CR11], [@CR12]\].

MRAs found initial use in HF exacerbations as diuretics in patients' refractory to combined ACEi and loop diuretic therapy \[[@CR13]\]. However, spironolactone at doses with no significant diuretic effect was found to reduce cardiovascular mortality \[[@CR14]\]. This effect was presumably due to a reduction in myocardial and vascular fibrosis \[[@CR14]\]. This effect may arise from spironolactone blocking aldosterone's ability to stimulate collagen synthesis at the myocardial level \[[@CR15]\]. Spironolactone and eplerenone have demonstrated significant mortality benefit in HFrEF \[[@CR11], [@CR12]\]. In contrast, MRAs in HFpEF do not reduce all-cause mortality, however, they do reduce hospitalizations, improve quality of life, and improve echocardiographic measurements of diastolic function \[[@CR16]\].

Chronically elevated aldosterone levels contribute towards structural changes in the heart which promote water retention, myocardial fibrosis, and increased arrhythmogenicity \[[@CR17]\]. MRAs in HFpEF improved echocardiographic and biochemical measures of diastolic function \[[@CR16], [@CR18]\]. However, a large prospective RCT in HFpEF patients treated with spironolactone did not demonstrate a significant benefit in terms of cardiovascular outcomes \[[@CR7]\].

Objectives {#Sec2}
----------

Our objectives were to evaluate the risks and benefits of MRA usage in adults with HF. We were particularly interested in differences between selective and nonselective MRAs in HFpEF and HFrEF in terms of cardiovascular outcomes and adverse effects.

Methods {#Sec3}
=======

Our systematic review and meta-analysis complies with the PRISMA statement \[[@CR19]\].

Eligibility criteria {#Sec4}
--------------------

We included randomized controlled trials (RCTs) of MRAs vs. placebo or standard therapy in adults (≥18 years old) with HFpEF or HFrEF. Included trials evaluated nonselective MRAs (e.g., canrenone, spironolactone), and selective MRAs (e.g., eplerenone, finerenone). Included trials contained at least one outcome of interest: mortality (all-cause or cardiovascular), cardiovascular hospitalizations, hyperkalemia, or gynecomastia.

Literature search {#Sec5}
-----------------

We searched the Cochrane Central Register of Controlled Trials (*The Cochrane Library* Issue 1, 2016), MEDLINE (January 1995 to January 29, 2016), and EMBASE (January 1995 to January 29, 2016) for articles meeting our inclusion criteria. Our search strategy for Ovid MEDLINE and EMBASE is in [Appendix 1](#Sec20){ref-type="sec"} and our search strategy for the Cochrane Register of Controlled Trials is in [Appendix 2](#Sec21){ref-type="sec"}. Our search did not have any language restrictions. We excluded reviews, editorials, and conferences but not unpublished studies or abstracts.

Study selection {#Sec6}
---------------

We entered the retrieved citations into Reference Manager (v12.0.3), and duplicate records were removed. One investigator (NB) screened citations for relevance based on their title and abstract. Both investigators reviewed the full text articles of relevant articles for study inclusion. Cohen's kappa statistic was used to quantify chance-corrected agreement between the investigators. Disagreements on study inclusion were resolved through a consensus process of having a discussion between the two investigators.

Data collection and analysis {#Sec7}
----------------------------

Both investigators extracted data independently from included articles. We resolved disagreements during data extraction by consensus. If data were incomplete or unclear we attempted to contact trial authors. We extracted the following items from each study: population (type of heart failure, study size), intervention (MRA type), control (placebo, none, other), and outcomes (all-cause mortality, cardiovascular mortality, hospitalizations, hyperkalemia, and gynecomastia/breast pain). We used each study's definition of these outcomes.

Risk of bias {#Sec8}
------------

Our risk of bias assessment was completed using the Cochrane Risk of Bias Tool. It evaluates individual studies for several biases: selection, performance, detection, attrition and reporting. We evaluated the quality of evidence for each outcome using GRADE criteria \[[@CR20]\], which evaluates an outcome across studies based on risk of bias, inconsistency, indirectness, imprecision and publication bias.

Statistical analysis {#Sec9}
--------------------

We obtained the relative risk for each outcome from the original study and used RevMan (version 5.3.5) and R \[[@CR21], [@CR22]\] to analyze data and generate figures. We used the Mantel-Haenszel method with a 95% confidence interval, and a random effects model to pool results. We quantified statistical heterogeneity using the I^2^ statistic. We interpreted an I^2^ value of 0--25% as low heterogeneity, 25--50% as moderate heterogeneity, and \>50% as high heterogeneity. *A priori* we established two hypotheses to explain potential heterogeneity: HF type (HFpEF and HFrEF), and MRA type (selective, or nonselective). We assessed for publication bias using funnel plots for each outcome.

Results {#Sec10}
=======

Trial selection {#Sec11}
---------------

We screened 2566 citations, and selected 36 for full text review. Of these, 15 articles \[[@CR7], [@CR11], [@CR12], [@CR18], [@CR23]--[@CR33]\] met our inclusion criteria and were included in our systematic review (see Fig. [1](#Fig1){ref-type="fig"}). Overall, there was excellent agreement on trial eligibility (Cohen's kappa 94%). We excluded articles from the systematic review because of treatment in a non-HF setting (*N* = 4), lack of relevant outcomes (*N* = 13), study duplication (*N* = 3), and not an RCT design (*N* = 1).Fig. 1Study selection flow diagram. Overview of process used to identify studies for inclusion in the systematic review. Three databases (MEDLINE, EMBASE, Cochrane) were searched for relevant articles. After identification, studies were screened against our inclusion criteria. Included studies were used in our meta-analysis

Trial characteristics {#Sec12}
---------------------

Table [1](#Tab1){ref-type="table"} reports the trial characteristics of the 15 RCTs containing 16321 patients. The patients had either HFpEF (*N* = 4027) or HFrEF (*N* = 12294) and the MRA treatment group was either nonselective, e.g., canrenone, spironolactone, *N* = 11 RCTs, 6678 patients; or selective, e.g., eplerenone, *N* = 4 RCTs, 9643 patients. Studies had an average length of follow-up of 15 months.Table 1Overview of trials meeting systematic review inclusion criteriaAuthorYearPopulationExp (N)Cont (N)InterventionDrug doseFollow-up (months)Akbulut2003HFrEF, EF ≤ 35%, NYHA III3535spironolactone25 mg daily3Boccanelli2009HFrEF, EF ≤ 45%, NYHA II215223canrenone25 mg daily12Chan2007HFrEF, EF \< 40%, NYHA I--III2325spironolactone25 mg daily12Cicoira2002HFrEF, EF ≤ 45%, NYHA III5452spironolactone25 mg daily12Deswal2011HFpEF, EF ≥ 50%, NYHA II--III2523eplerenone25 mg daily6Edelmann2013HFpEF, EF ≥ 50%, NYHA II--III213209spironolactone25 mg daily12Edwards2009HFpEF, CKD stage 2--35656spironolactone25 mg daily9Zannad2011HFrEF, EF ≤ 35%, NYHA II13641373eplerenone25--50 mg daily21Pitt2003MI + HFrEF, EF ≤ 40%33193313eplerenone25--50 mg daily16Gao2007HFrEF, EF \< 45%, NYHA II--IV5858spironolactone20 mg daily6Pitt2013HFrEF, EF ≤ 40%, CKD stage 2--36365spironolactone25--50 mg daily1Pitt1999HFrEF, EF \< 35%, NYHA III--IV822841spironolactone25--50 mg daily24Pitt2014HFpEF, EF ≥ 45%17221723spironolactone15--45 mg daily40Udelson2010HFrEF, EF ≤ 35% NYHA II--III117109eplerenone50 mg daily9Vizzardi2014HFrEF, EF \< 40%, NYHA I--II6565spironolactone25--100 mg daily44

Risk of bias within included trials {#Sec13}
-----------------------------------

Table [2](#Tab2){ref-type="table"} reports the quality of included studies. Five trials had unclear or absent allocation concealment \[[@CR23], [@CR25], [@CR26], [@CR28], [@CR30]\]. Two studies had inadequate blinding and were of single-blind design \[[@CR23], [@CR32]\]. Two large studies were terminated early due to meeting pre-defined benefit criteria \[[@CR11], [@CR33]\]. Another two studies did not use intention-to-treat analysis. Overall, loss-to-follow-up was low with a range of 0 to 6.6%.Table 2Risk of bias summary for each study included in the meta-analysisAuthorYearAllocation concealmentBlindingIntention to treat analysisLoss to follow-up (%)Early trial terminationAkbulut2003UnclearNoYes0.0NoBoccanelli2009YesYesYes6.2NoChan2007UnclearYesYes0.0NoCicoira2002UnclearYesYes6.6NoDeswal2011YesYesNo4.3NoEdelmann2013YesYesYes1.2NoEdwards2009UnclearYesNo2.7NoZannad2011YesYesYes1.2YesPitt2003YesYesYes0.3NoGao2007YesYesYes0.0NoPitt2013No (open label Aldactone)YesYes0.0NoPitt1999YesYesYes0.0YesPitt2014YesYesYes3.8NoUdelson2010YesYesYes0.0NoVizzardi2014YesNoYes0.0No

Results of meta-analysis {#Sec14}
------------------------

Table [3](#Tab3){ref-type="table"} reports a summary of findings. We included outcomes for cardiovascular death (7 RCTs), all-cause mortality (12 RCTs), cardiac hospitalization (10 RCTs), hyperkalemia (15 RCTs), and gynecomastia (*N* = 11 RCTs). Quality of evidence for cardiovascular death, all-cause mortality, and cardiac hospitalization were rated moderate; hyperkalemia and gynecomastia were rated high using GRADE guidelines \[[@CR20]\]. For each outcome, HFrEF evidence was of high quality, but the quality of evidence for HFpEF was of moderate quality for all-cause mortality, cardiovascular death, and cardiac hospitalizations.Table 3Summary of findings for the effect of mineralocorticoid receptor antagonists in treating Heart FailureOutcome№ of participants (studies)Quality of the evidence (GRADE)Relative effect (95% CI)Anticipated absolute effectsRisk with placeboRisk difference with MRACardiovascular death15115\
(7 RCTs)⨁⨁⨁\
MODERATE^a^RR 0.81\
(0.75 to 0.87)155 per 100029 fewer per 1000\
(39 fewer to 20 fewer)Cardiovascular death - rEF11670\
(6 RCTs)⨁⨁⨁⨁\
HIGHRR 0.79\
(0.73 to 0.86)171 per 100036 fewer per 1000\
(46 fewer to 24 fewer)Cardiovascular death - pEF3445\
(1 RCT)⨁⨁⨁\
MODERATE^b^RR 0.91\
(0.74 to 1.11)102 per 10009 fewer per 1000\
(27 fewer to 11 more)All cause mortality15919\
(12 RCTs)⨁⨁⨁\
MODERATE^c^RR 0.83\
(0.77 to 0.88)182 per 100031 fewer per 1000\
(42 fewer to 22 fewer)All cause mortality - rEF11892\
(8 RCTs)⨁⨁⨁⨁\
HIGHRR 0.81\
(0.75 to 0.87)197 per 100038 fewer per 1000\
(49 fewer to 26 fewer)All cause mortality - pEF4027\
(4 RCTs)⨁⨁⨁\
MODERATE^d^RR 0.92\
(0.79 to 1.08)136 per 100011 fewer per 1000\
(29 fewer to 11 more)Cardiac hospitalization15669\
(10 RCTs)⨁⨁⨁\
MODERATE^d^RR 0.80\
(0.70 to 0.92)217 per 100043 fewer per 1000\
(65 fewer to 17 fewer)Cardiac hospitalization - rEF11754\
(7 RCTs)⨁⨁⨁\
MODERATE^d^RR 0.76\
(0.64 to 0.90)245 per 100059 fewer per 1000\
(88 fewer to 24 fewer)Cardiac hospitalization - pEF3915\
(3 RCTs)⨁⨁⨁\
MODERATE^d^RR 0.91\
(0.67 to 1.24)134 per 100012 fewer per 1000\
(44 fewer to 32 more)Hyperkalemia16321\
(15 RCTs)⨁⨁⨁⨁\
HIGHRR 2.03\
(1.78 to 2.31)37 per 100039 more per 1000\
(29 more to 49 more)Gynecomastia or breast pain - nonselective6432\
(8 RCTs)⨁⨁⨁⨁\
HIGHRR 7.37\
(4.42 to 12.30)5 per 100030 more per 1000\
(16 more to 53 more)Gynecomastia or breast pain - selective9417\
(3 RCTs)⨁⨁⨁⨁\
HIGHRR 0.74\
(0.43 to 1.27)7 per 10002 fewer per 1000\
(4 fewer to 2 more)*CI* Confidence interval, *RR* Risk ratio^a^High quality of evidence for HFrEF, single study for HFpEF^b^Single trial with confidence interval which crossed unity^c^High quality of evidence for HFrEF, moderate quality evidence for HFpEF^d^Confidence interval of data crossed unity

Meta-analysis of cardiovascular death (see Fig. [2](#Fig2){ref-type="fig"}) revealed a significant risk reduction, RR 0.81 \[0.75--0.87\], I^2^ 0% (low heterogeneity). Our analysis of cardiovascular death by HF type indicated only a single trial of HFpEF (TOPCAT) which had no significant reduction in cardiovascular death \[[@CR7]\]. Using either selective or nonselective MRA had a similar reduction in cardiovascular death (Additional file [1](#MOESM1){ref-type="media"}: Figure S1).Fig. 2Forest plot of cardiovascular death with MRA use in HF. Seven trials reported cardiovascular death rates when using MRAs in HF compared to control. Our Forest plot has been subdivided according to HF type

Meta-analysis of all-cause mortality (see Fig. [3](#Fig3){ref-type="fig"}) revealed a significant risk reduction, RR 0.83 \[0.77--0.88\], I^2^ 0% (low heterogeneity). HF type subgroups indicated the benefit was limited to HFrEF. Use of either a selective or nonselective MRA had a similar reduction in all-cause mortality (Additional file [2](#MOESM2){ref-type="media"}: Figure S2).Fig. 3Forest plot of all-cause mortality with MRA use in HF. Twelve trials reported all-cause mortality rates with MRA use in HF compared to control. Our Forest plot has been subdivided according to HF type

Meta-analysis of cardiac hospitalizations (see Fig. [4](#Fig4){ref-type="fig"}) revealed a significant risk reduction, RR 0.80 \[0.70--0.92\], I^2^ 58.4% (high heterogeneity). Our *a priori* subgroup analysis partially explained the heterogeneity within this outcome, as a significant reduction in cardiac hospitalizations was found in the HFrEF and nonselective MRA subgroups (Additional file [3](#MOESM3){ref-type="media"}: Figure S3).Fig. 4Forest plot of cardiovascular hospitalizations with MRA use in HF. Ten trials reported cardiovascular hospitalization rates with MRA use in HF compared to control. Our Forest plot has been subdivided according to HF type

Hyperkalemia was significantly more common with MRA use, RR 2.03 \[1.78--2.31\], I^2^ 0% (low heterogeneity), see Fig. [5](#Fig5){ref-type="fig"}. Subgroup analysis by MRA or HF type did not significantly influence the rate of hyperkalemia (Additional file [4](#MOESM4){ref-type="media"}: Figure S4).Fig. 5Forest plot of hyperkalemia with MRA use in HF. Fifteen trials reported hyperkalemia rates with MRA use in HF compared to control. Our Forest plot has been subdivided according to HF type

Gynecomastia was significantly more common with MRA use, RR 3.28 \[1.18--9.10\], I^2^ 81.7% (high heterogeneity), see Fig. [6](#Fig6){ref-type="fig"}. MRA type explained this heterogeneity as selective MRAs did not produce significant amounts of gynecomastia (RR 0.74 \[0.43--1.27\], I^2^ 0%) while nonselective MRAs did (RR 7.37 \[4.42--12.30\], I^2^ 0%).Fig. 6Forest plot of gynecomastia with MRA use in HF. Eleven trials reported gynecomastia rates with MRA use in HF compared to control. Our Forest plot has been subdivided according to MRA type

Our analysis of funnel plots for each outcome except gynecomastia revealed no significant asymmetry (Additional file [5](#MOESM5){ref-type="media"}: Figure S5, Additional file [6](#MOESM6){ref-type="media"}: Figure S6, Additional file [7](#MOESM7){ref-type="media"}: Figure S7, Additional file [8](#MOESM8){ref-type="media"}: Figure S8 and Additional file [9](#MOESM9){ref-type="media"}: Figure S9) and suggested the absence of publication bias. Two MRA subgroups within the funnel plot for gynecomastia explained the asymmetry of the plot (Additional file [9](#MOESM9){ref-type="media"}: Figure S9).

Discussion {#Sec15}
==========

Summary of evidence {#Sec16}
-------------------

15 trials evaluated the use of MRAs compared to placebo or no treatment for HF. MRA use in patients with heart failure was associated with a significant reduction in adverse cardiovascular outcomes: cardiovascular death (RR 0.81 \[0.75--0.87\], I^2^ 0%), all-cause mortality (RR 0.83 \[0.77--0.88\], I^2^ 0%), and cardiac hospitalizations (RR 0.80 \[0.70--0.92\], I^2^ 58.4%). *Our a priori* specified subgroup analysis demonstrated that the benefits of MRAs are limited to HFrEF. Both selective and nonselective MRAs increase the risk of hyperkalemia (RR 2.03 \[1.78--2.31\], I^2^ 0%), but gynecomastia is limited to nonselective MRAs (nonselective MRAs RR 7.37 \[4.42--12.30\], I^2^ 0% vs. selective MRAs RR 0.74 \[0.43--1.27\], I^2^ 0%RR 7.37 \[4.42--12.30).

Strengths and limitations {#Sec17}
-------------------------

Our systematic review has strengths including adherence to PRISMA reporting guidelines. In addition, our conclusions are based on evidence of moderate and high quality (GRADE). HFpEF evidence was of moderate quality, and HFrEF evidence was of high quality for cardiovascular death and all-cause mortality. The quality of evidence for cardiovascular death and all-cause mortality was reduced due the evidence for MRA use in HFpEF being limited to a single trial with large effect size \[[@CR7]\], and several smaller trials with confidence intervals crossing unity \[[@CR18], [@CR27], [@CR28]\]. For cardiovascular hospitalizations, the quality of evidence was reduced by confidence intervals in HFpEF and HFrEF studies crossing unity \[[@CR7], [@CR33]\]. Evidence for hyperkalemia and gynecomastia with MRA usage was of high quality. Overall, the evidence supporting MRA use in HFrEF is based on a larger number of trials with significant effect sizes for reducing adverse cardiac events. In contrast, the evidence for MRA use in HFpEF is based on a smaller number of trials, only one of which had a significant reduction in cardiovascular hospitalizations but no other adverse cardiac events \[[@CR7]\]. Finally, our conclusions supporting MRA usage in HFrEF align with current American Heart Association guidelines which recommend MRAs for patients with HFrEF and NYHA class II-IV symptoms or following acute MI complicated by HF and EF ≤ 40% \[[@CR1]\].

Implications {#Sec18}
------------

Current guidelines suggest MRAs are useful in treating HFrEF and acute MI complicated by HF \[[@CR1], [@CR34]\]. We demonstrate that treatment of HFpEF with MRAs does not reduce adverse cardiac events. However, MRAs do cause harm from hyperkalemia (NNH 26 \[20--34\]) and gynecomastia (e.g., nonselective MRA, NNH 33 \[19--63\]). Selective MRAs offer a slight advantage in terms of no significant gynecomastia while having equivalent reductions in adverse cardiac outcomes. We suggest continued usage of MRAs in HFrEF, where there is a significant reduction in adverse cardiac outcomes, e.g., cardiovascular death (NNT 34 \[26--50\]), or all-cause mortality (NNT 32 \[24--45\]). We suggest that MRAs be avoided in HFpEF as they do not reduce adverse cardiovascular outcomes.

Conclusions {#Sec19}
===========

Our systematic review provides evidence that MRAs should not be used in HFpEF. MRA usage in HFpEF provides a risk of hyperkalemia and/or gynecomastia without reducing adverse cardiac events. In contrast, MRA usage in HFrEF significantly reduces adverse cardiac events.

Appendix 1 {#Sec20}
==========

Table 4Ovid MEDLINE and EMBASE search strategy1Exp heart failure/376335/948362Exp Cardiomyopathy/113241/782243Exp Ventricular dysfunction/13819/289654((heart or cardiac or myocardial) adj2 (failure or decompensation)).ti,ab211838/1301255((congestive or chronic) adj2 heart failure).ti,ab67554/456136((ventric\$) adj2 (failure or insufficien\$ or dysfunction\$ or function\$)).ti,ab82523/547727((Reduced or preserved) adj2 \"ejection fraction\").ti,ab.6293/28568(HFpEF or HFrEF).mp2216/7769((diastol\$ or systol\$) adj2 ((failure or dysfunction\$ or function\$)).ti,ab48968/2752310Or/1-9538115/27599511(animal\$ not (human\$ and animal\$)).sh,hw.3987846/41373271210 NOT 11501141/24162613exp Aldosterone Antagonist/32899/812414(eplerenone or inspra or spironolactone or aldactone or aldo\$ or mineralocorticoid receptor antagon\$ or canren\$ or fineren\$). ti,ab134477/6366715(aldosterone adj2 antagon\$). ti,ab7857/206616Or/13-15134563/636671716 NOT 11111915/467941812 and 1720116/488019(1995\* or 1996\* or 1997\* or 1998\* or 1999\* or 2000\* or 2001\* or 2002\* or 2003\* or 2004\* or 2005\* or 2006\* or 2007\* or 2008\* or 2009\* or 2010\* or 2011\* or 2012\* or 2013\* or 2014\* or 2015\* or 2016\*).dd21741062/020(1995\* or 1996\* or 1997\* or 1998\* or 1999\* or 2000\* or 2001\* or 2002\* or 2003\* or 2004\* or 2005\* or 2006\* or 2007\* or 2008\* or 2009\* or 2010\* or 2011\* or 2012\* or 2013\* or 2014\* or 2015\* or 2016\*).ed0/163098192119 or 2021741062/163098192218 AND 2117787/373523(book or conference paper or editorial or letter or review).pt. not exp randomized controlled trial/4298634/331984324(random sampl\$ or random digit\$ or random effect\$ or random survey or random regression).ti,ab. not exp randomized controlled trial/69917/5600125(random\$ or placebo\$ or single blind\$ or double blind\$ or triple blind\$).ti,ab.1177770/8847502625 not (23 or 24 or 11)908857/6487722722 and 261802/503 = 230528Remove duplicates from 271372/502 = 1874(Search performed January 29, 2016)

Appendix 2 {#Sec21}
==========

Table 5Cochrane database search strategy1exp heart failure14122exp Cardiomyopathy1333exp Ventricular dysfunction2254((heart or cardiac or myocardial) near/2 (failure or decompensation)):ti,ab,kw149415((congest\* or chronic) near/2 \"heart failure\"):ti,ab,kw61586(ventric\* near (fail\* or insufficien\* or dysfunction\* or function\*)):ti,ab,kw90677((diastol\* or systol\*) near/2 (failure or dysfunction\* or function\*)):ti, ab, kw28668((Reduced or preserved) near/2 (ejection or fraction or "EF")):ti, ab, kw5329("HFpEF" or "HFrEF"):ti, ab, kw16110\#1 or \#2 or \#3 or \#4 or \#5 or \#6 or \#7 or \#8 or \#92198311exp Aldosterone Antagonist\*4412(mineralocorticoid receptor antagonist\*):ti,ab,kw48613(eplerenone or inspra or spironolactone or aldactone or canren\* or fineren\*):ti,ab,kw130914Aldosterone near/2 antagon\*39315\#11 or \#12 or \#13166116\#10 and \#15692Updated Jan-29-2016

Additional files {#Sec22}
================

Additional file 1: Figure S1.Forest plot of cardiovascular death in HF with MRA use by MRA type. (EPS 2561 kb) Additional file 2: Figure S2.Forest plot of all-cause mortality in HF with MRA use by MRA type. (EPS 2763 kb) Additional file 3: Figure S3.Forest plot of cardiovascular hospitalization with MRA use by MRA type. (EPS 2740 kb) Additional file 4: Figure S4.Forest plot of hyperkalemia with MRA use by MRA type. (EPS 2919 kb) Additional file 5: Figure S5.Funnel plot of cardiovascular death with MRA use. (EPS 737 kb) Additional file 6: Figure S6.Funnel plot of all-cause mortality with MRA use. (EPS 736 kb) Additional file 7: Figure S7.Funnel plot of cardiovascular hospitalizations with MRA use. (EPS 710 kb) Additional file 8: Figure S8.Funnel plot of hyperkalemia with MRA use. (EPS 736 kb) Additional file 9: Figure S9.Funnel plot of gynecomastia with MRA use. (EPS 743 kb)

HF

:   Heart failure

HFpEF

:   Heart failure with preserved ejection fraction

HFrEF

:   Heart failure with reduced ejection fraction

MI

:   Myocardial infarction

MRA

:   Mineralocorticoid receptor antagonist

NNH

:   Number needed to harm

NNT

:   Number needed to treat

NYHA

:   New York Heart Association

RCT

:   Randomized controlled trial

RR

:   Relative risk
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